Race Oncology Ltd (ASX:RAC) Initiates Phase 1 RC220 + Doxorubicin Trial
Trial Initiation
Race Oncology Ltd (ASX:RAC) has safely dosed the first patient with the RC220 and doxorubicin combination in its Phase 1 clinical trial for advanced solid tumours at Southside Cancer Care Centre, Miranda, NSW.
Safety Observations
No treatment-related dose-limiting adverse side effects were observed during the initial dosing of the first patient.
Future Plans
The Phase 1 trial is open-label and will be conducted across multiple sites in Australia, Hong Kong, and South Korea. Race Oncology plans to activate additional sites and will announce progress updates as significant milestones are met.
Executive Comments
Vice President of Medical, Dr Simon Fisher stated, “The initiation of this trial and the early safety observations are encouraging. We are partnering well with our Australian sites and working diligently to activate additional sites in Hong Kong and South Korea. We remain excited with the progress of RC220 in the clinic and its potential to offer an improved treatment option for the many patients at risk of cardiotoxicity related to doxorubicin therapy.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
